CYP2B1-expressing ProCon vector (Bavarian Nordic)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCYP2B1-expressing ProCon vector (Bavarian Nordic)

Drug Alias NameCYP2B1-expressing Promoter Conversion vector (Bavarian Nordic)pancreatic cancer suicide gene therapy (Bavarian Nordic)breast cancer suicide gene therapy (Bavarian Nordic)

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsPancreatic NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBavarian Nordic A/S

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBavarian Nordic A/S

Active IndicationsN/A

Inactive IndicationsPancreatic NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A